【摘要】 目的探讨口服N-乙酰半胱氨酸对老年慢性阻塞性肺疾病患者急性加重的影响。方法选择120例C和D型的稳定期老年慢性阻塞性肺疾病患者,按照随机数字表法分为3组:低剂量组、高剂量组和对照组,每组40例。低剂量组每天口服1次N-乙酰半胱氨酸片,每次0.6 g,高剂量组每天口服2次N-乙酰半胱氨酸片,每次0.6 g,对照组不予该药,均观察6个月。比较3组患者急性加重的次数、天数和严重程度等。结果与对照组比较,高剂量组急性加重次数和天数均低于对照组(均P<0.05),而低剂量组急性加重次数和天数均无明显差异(均P>0.05)。高剂量组和低剂量组的Ⅱ级和Ⅲ级急性加重事件发生概率均低于对照组(均P<0.05)。结论每日口服高剂量N-乙酰半胱氨酸能减少慢性阻塞性肺疾病患者的急性加重次数,缩短急性加重天数,并减少中重度急性加重事件发生,而每日口服低剂量N-乙酰半胱氨酸不能减少急性加重发生,但可减轻其急性加重的严重程度。更多还原

【Abstract】 Objective To explore the impact of different oral doses of N-acetylcysteine(NAC) on the exacerbation of chronic obstructive pulmonary disease(COPD). Methods 120 elderly with COPD of type C and D at stationary period were selected and randomly divided into 3 groups: low-dose group, high-dose group and control group, 40 in each; oral administration of NAC(0.6 g) was made to patients in low-dose group, once a day while that was made to patients in high-dose group, twice a day; no oral administration of NAC was made to patients in control group; other therapeutic measures in the 3 groups were same and a continuous observation was made to all the patients in the 3 groups. Results The times and days of exacerbation of the patients in high-dose group were both less than those of the patients in control group( P<0.05) while no obvious difference in times and days of exacerbation was found between the patients in low-dose group and patients in control group( P>0.05); the occurrence probability of exacerbation of Grade Ⅱ and Ⅲ in low-dose group and high-dose group were lower than that in control group( P<0.05). Conclusions Daily oral administration of high-dose NAC can cut down the times of exacerbation occurrence in COPD patients, shorten the days of exacerbation and decrease the occurrence of moderate or severe exacerbation; daily oral administration of low-dose NAC can alleviate the severity of exacerbation though it cannot cut down the occurrence of exacerbation.更多还原